• Coordinate overall management with patient’s internist/primary
care physician since treatment of this disease requires systemic immunosuppression and/or use of anti-inflammatory drugs.
• Management of oral lesions will consist of systemic immunosuppressive agents.
care physician since treatment of this disease requires systemic immunosuppression and/or use of anti-inflammatory drugs.
• Management of oral lesions will consist of systemic immunosuppressive agents.
• Local/intralesional therapy may be a useful adjunct following an initial good measurable response to systemic glucocorticosteroid dosing.
• Systemic therapy: prednisone 10 mg tablets #150 • Take each morning with breakfast at a total daily dose of
1 mg/kg of body weight. • Taper slowly over several months as clinical response
permits to maintenance dosing. • Management of prednisone side effects is important.
• Corticosteroid-sparing systemic therapy • Azathioprine 1–3 mg/kg; dosing spaced morning and evening • Mycophenolate mofetil 500 mg tablets; 1.5 g bid
• Severe or unresponsive disease • Plasmapheresis • Pulse cyclophosphamide (Cytoxan) IV for 3 wk
– Monitor response. – Continue on orally administered immunosuppressants.
• IVIg therapy • Local therapy for focal residual lesions: intralesional
triamcinolone suspension 10 mg/mL
• Systemic therapy: prednisone 10 mg tablets #150 • Take each morning with breakfast at a total daily dose of
1 mg/kg of body weight. • Taper slowly over several months as clinical response
permits to maintenance dosing. • Management of prednisone side effects is important.
• Corticosteroid-sparing systemic therapy • Azathioprine 1–3 mg/kg; dosing spaced morning and evening • Mycophenolate mofetil 500 mg tablets; 1.5 g bid
• Severe or unresponsive disease • Plasmapheresis • Pulse cyclophosphamide (Cytoxan) IV for 3 wk
– Monitor response. – Continue on orally administered immunosuppressants.
• IVIg therapy • Local therapy for focal residual lesions: intralesional
triamcinolone suspension 10 mg/mL